Process for preparation of Darunavir
The present invention provides a process for the preparation of darunavir or solvates or a pharmaceutically acceptable salt thereof substantially free of bisfuranyl impurities, particularly darunavir propionate solvate. The present invention also provides a process for preparation amorphous darunavir using the darunavir propionate solvate.
1. A process for preparation of amorphous darunavir, comprising the steps of:
a) providing a first solution comprising an acid and a solvent, at a temperature of about −5° C. to about 10° C., wherein the acid is acetic acid and the solvent is either acetonitrile or water;
b) adding an amount of darunavir propionate solvate to the first solution to form a second solution;
c) combining the second solution of step b) with a base and water at a temperature of about −10° C. to about 0° C., wherein the base is ammonia to form a third solution; and
c) recovering the amorphous darunavir from the third solution of step b), wherein the purity of the amorphous darunavir is equal to or greater than about 99.7% as measured by HPLC.
2. The process of claim 1 , wherein the solvent used in the first solution of step a) is acetonitrile.
3. The process of claim 1 , wherein the first solution of step a) is provided at a temperature of about 5° C. to about 10° C.
4. The process of claim 1 , wherein the third solution formed in step b) is subsequently stirred at a temperature of about −10° C. to about −5° C.
5. The process of claim 1 , further comprising forming a pharmaceutical composition by combining the recovered amorphous darunavir with at least one pharmaceutically acceptable excipient.
6. A process for preparation of amorphous darunavir, comprising the steps of:
a) forming a first solution by dissolving a darunavir solvate in an acid and a solvent at a temperature of about −5° C. to about 10° C., wherein the acid is acetic acid and the solvent is either acetonitrile or water;
b) combining the first solution with a second solution comprising a base and water at a temperature of about −10° C. to about 0° C. to form a third solution; and
c) recovering by filtration the amorphous darunavir from the third solution, wherein the purity of the amorphous darunavir is equal to or greater than about 99.7% as measured by HPLC.
7. The process of claim 6 , further comprising:
d) combining the recovered amorphous darunavir with at least one pharmaceutically acceptable excipient for use as a pharmaceutical composition.
8. The process of claim 6 , wherein the purified amorphous darunavir includes less than 0.04% as measured by HPLC of any one of: